Inflammation, allergy and asthma, complex immune origin diseases: Mechanisms and therapeutic agents

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 7, Issue 1, 2013, Pages 62-95

  Naik, Suresh R ^a   Wala, Santosh M ^a  

^a Sinhgad Institute of Pharmaceutical Sciences   (India)

Author keywords

Allergy; Asthma; Cytokines; Effector cells; Eicosanoids; Inflammation; Oxidative stress; Patents; Therapeutics

Indexed keywords

ACETYLSALICYLIC ACID; ALLERGEN; BENORILATE; CATALASE; CHEMOKINE; CYTOKINE; HYDROCORTISONE; ICOSANOID; LEUKOTRIENE; LIPOXYGENASE; METHYLPREDNISOLONE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENYLBUTAZONE; PHOSPHOLIPASE A2; PREDNISOLONE; PREDNISONE; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN D2; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTAGLANDIN F2; PROSTAGLANDIN SYNTHASE; REACTIVE OXYGEN METABOLITE; THROMBOXANE; TRANSFORMING GROWTH FACTOR; TRIAMCINOLONE; UNINDEXED DRUG;

ALLERGY; ASTHMA; B LYMPHOCYTE; BASOPHIL; BLOOD VESSEL PERMEABILITY; BRONCHOSPASM; CARTILAGE DEGENERATION; CELL MIGRATION; DENDRITIC CELL; DRUG MECHANISM; DRUG STRUCTURE; EFFECTOR CELL; EOSINOPHIL; HUMAN; IMMUNE RESPONSE; INFLAMMATION; KALLIKREIN KININ SYSTEM; LEUKOCYTE; LIPID PEROXIDATION; LUNG FUNCTION; MACROPHAGE; MAST CELL; MONOCYTE; MUCUS SECRETION; NATURAL KILLER CELL; NEUTROPHIL; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VASODILATATION;

EID: 84874913428     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221313804004682     Document Type: Review

References (287)

1. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454: 428-35.
2. Germolec DR, Frawley RP, Evans E. Markers of inflammation. Methods Mol Biol 2010; 598: 53-73.
3. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5(12): 953-64.
4. Duvall E, Wyllie AH, Morris RG. Macrophage recognition of cells undergoing programmed cell death (apoptosis). Immunology 1985; 56: 351-8.
5. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. Ann Rev Immunol 2000; 18(1): 767-811.
6. Murphy DM, O'Byrne PM. Recent advances in the pathophysiology of asthma. Chest 2010; 137: 1417-26.
7. Bloemen K, Verstraelen S, Heuvel Van Den R, Witters H, Nelissen I, Schoeters G. The allergic cascade: Review of the most important molecules in the asthmatic lung. Immunol Lett 2007; 113: 6-18.
8. Bharadwaj A, Agrawal DK. Immunomodulation in asthma: A distant dream or a close reality. Int Immunopharmacol 2004; 4: 495-511.
9. Bergeron C, Boulet LP. Structural changes in airway diseases: Characteristics, mechanisms, consequences, and pharmacologic modulation. Chest 2006; 129: 1068-87.
10. Serhan CN, Yacoubian S, Yang R. Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol 2008; 3: 279-312.
11. Massey KA, Nicolaou A. Lipidomics of polyunsaturated-fatty-acidderived oxygenated metabolites. Biochem Soc Trans 2011; 39: 1240-6.
12. Serhan CN, Haeggstrom JZ. Lipid mediators in acute inflammation and resolution: Eicosanoids, PAF, resolvins, and protectins. Cambridge University Press, 2009.
13. Pagels WR, Sachs RJ, Marnett LJ, Dewitt DL, Day JS, Smith WL. Immunochemical evidence for the involvement of prostaglandin H synthase in hydroperoxide-dependent oxidations by ram seminal vesicle microsomes. J Biol Chem 1983; 258: 6517-23.
14. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004; 56: 387-437.
15. Cipollone F, Cicolini G, Bucci M. Cyclooxygenase and prostaglandin synthases in atherosclerosis: Recent insights and future perspectives. Pharmacol Ther 2008; 118: 161-80.
16. Samad TA, Sapirstein A, Woolf CJ. Prostanoids and pain: Unravelling mechanisms and revealing therapeutic targets. Trends Mol Med 2002; 8: 390-6.
17. Hirata T, Narumiya S. Prostanoid receptors. Chem Rev 2011; 111: 6209-30.
18. Narumiya S. Prostanoids and inflammation: A new concept arising from receptor knockout mice. J Mol Med 2009; 87: 1015-22.
19. Narumiya S, Furuyashiki T. Fever, inflammation, pain and beyond: Prostanoid receptor research during these 25 years. FASEB J 2011; 25: 813-8.
20. Funk CD. Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science 2001; 294:1871-5.
21. Busse W, Kraft M. Cysteinyl leukotrienes in allergic inflammation: Strategic target for therapy. Chest 2005; 127: 1312-26.
22. Werz O, Steinhilber D. Development of 5-lipoxygenase inhibitorslessons from cellular enzyme regulation. Biochem Pharmacol 2005; 70: 327-33.
23. Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med 2007; 357: 1841-54.
24. Shimizu T. Lipid mediators in health and disease: Enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol 2009; 49: 123-50.
25. Zhao L, Moos MP, Grabner R, Pedrono F, Fan J, Kaiser B, et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med 2004; 10: 966-73.
26. Campbell DJ. The kallikrein-kinin system in humans. Clin Exp Pharmacol Physiol 2001; 28: 1060-5.
27. Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, Adam A. The kallikrein-kinin system: Current and future pharmacological targets. J Pharmacol Sci 2005; 99: 6-38.
28. Erdos E, Kinins G. The long march, A personal view. Cardiovasc Res 2002; 54: 485-91.
29. Calixto JB, Cabrini DA, Ferreira J, Campos MM. Kinins in pain and inflammation. Pain 2000; 87:1-5.
30. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: From molecular mechanisms to pathophysiological consequences. Pharmacol Rev 2005; 57: 27-77.
31. Bhoola KD, Fink E. Kallikrein-kinin cascade. In: Laurent GJ, Shapiro SD, Eds. Encyclopedia of respiratory medicine. Oxford, UK: Elsevier, 2005.
32. Wollert KC, Drexler H. The kallikrein-kinin system in post myocardial infarction cardiac remodeling. Am J Cardiol 1997; 80: 158A.
33. Dinarello CA. Historical insights into cytokines. Eur J Immunol 2007; 37(1): S34-S45.
34. Waage A, Halstensen A, Shalaby R, Brandtzaeg P, Kierule P, Esperik T. Local production of tumor necrosis factor-a, interleukin-1, and interleukin-6 in meningococeal meningitis: Relation to the inflammatory response. J Exp Med 1989; 170:1859-67.
35. Slifka MK, Whitton JL. Clinical implications of dysregulated cytokine production. J Mol Med 2000; 78:74-80.
36. Hopkins SJ, Meager A. Cytokines in synovial fluid. Clin Exp Immunol 1988; 73: 88-92.
37. Ramilo O, Mustafa MM, Porter J, Saez-Llorens X, Mertsola J, Olsen KD, et al. Detection of interleukin 1 but not tumor necrosis factor-β in cerebrospinal fluid of children with aseptic meningitis. Am Dis Child 1990; 144: 349-52.
38. Mathiesen T, Edner G, Ulfarsson E, Andersson B. Cerebrospinal fluid interleukin-1 receptor antagonist and tumor necrosis factoralpha following subarachnoid hemorrhage. J Neurosurg 1997; 87: 215-20.
39. Wang LJ, Norman RJ. Concentrations of immunoreactive interleukin-1 and interleukin-2 in human preovulatory follicular-fluid. Hum Reprod 1992; 7: 147-50.
40. Jones KP, Reynolds SP, Capper SJ, Kalinka S, Edwards JH, Davies BH. Measurement of interleukin-6 in bronchoalveolar lavage fluid by radioimmunoassay: Differences between patients with interstitial lung disease and control subjects. Clin Exp Immunol 1991; 83: 30-4.
41. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27: 519-50.
42. Malek TR. The biology of interleukin-2. Annu Rev Immunol 2008; 26: 453-79.
43. Asquith KL, Ramshaw HS, Hansbro PM, Beagley KW, Lopez AF, Foster PS. The IL-3/IL-5/GM-CSF common receptor plays a pivotal role in the regulation of Th2 immunity and allergic airway inflammation. J Immunol 2008; 180: 1199-206.
44. Wang X, Lupardus P, Laporte SL, Garcia KC. Structural biology of shared cytokine receptors. Annu Rev Immunol 2009; 27: 29-60.
45. Yang M, Hogan SP, Mahalingam S, Pope SM, Zimmermann N, Fulkerson P, et al. Eotaxin-2 and IL-5 cooperate in the lung to regulate IL-13 production and airway eosinophilia and hyperreactivity. J Allergy Clin Immunol 2003; 112: 935-43.
46. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001; 14: 705-14.
47. Welch PA, Namen AE, Goodwin RG, Armitage R, Cooper MD. Human IL-7: A novel T cell growth factor. J Immunol 1989; 143:3562-7.
48. Holmes WE, Lee J, Kuang WJ, Rice GC, Wood WI. Structure and functional expression of a human interleukin-8 receptor. Science 1991; 253: 1278-80.
49. Houssiau FA, Renauld JC, Fibbe WE, Van Snick J. IL-2 dependence of IL-9 expression in human T lymphocytes. J Immunol 1992; 148: 3147-51.
50. Commins S, Steinke JW, Borish L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol 2008; 121: 1108-11.
51. Paul SR, Schendel P. The cloning and biological characterization of recombinant human interleukin 11. Int J Cell Cloning 1992; 10: 135-43.
52. Chua AO, Chizzonite R, Desai BB, Truitt TP, Nunes P, Minetti LJ, et al. Expression cloning of a human IL-12 receptor component: A new member of the cytokine receptor superfamily with strong homology to gp130. J Immunol 1994; 153: 128-36.
53. LaPorte SL, Juo ZS, Vaclavikova J, Colf LA, Qi X, Heller NM, et al. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell 2008; 132: 259-72.
54. Shen L, Zhang C, Wang T, Brooks S, Ford RJ, Lin-Lee YC, et al. Development of autoimmunity in IL-14alpha-transgenic mice. J Immunol 2006; 177: 5676-86.
55. Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000; 191: 771-80.
56. De Bie JJ, Jonker EH, Henricks PA, Hoevenaars J, Little FF, Cruikshank WW, et al. Exogenous interleukin-16 inhibits antigeninduced airway hyper-reactivity, eosinophilia and Th2-type cytokine production in mice. Clin Exp Allergy 2002; 32: 1651-8.
57. Hwang SY, Kim HY. Expression of IL-17 homologs and their receptors in the synovial cells of rheumatoid arthritis patients. Mol Cells 2005; 19: 180-4.
58. Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 2008; 223: 20-38.
59. Gallagher G, Dickensheets H, Eskdale J, Izotova LS, Mirochnitchenko OV, Peat JD, et al. Cloning, expression and initial characterization of interleukin-19 (IL-19), a novel homologue of human interleukin-10 (IL-10). Genes Immun 2000; 1: 442-50.
60. Hsieh MY, Chen WY, Jiang MJ, Cheng BC, Huang TY, Chang MS. Interleukin-20 promotes angiogenesis in a direct and indirect manner. Genes Immun 2006; 7: 234-42.
61. Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007; 448: 484-7.
62. Cella M, Fuchs A, Vermi W, Facchetti F, Otero K, Lennerz JK, et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 2009; 457: 722-5.
63. Buonocore S, Ahern PP, Uhlig HH, Ivanov II, Littman DR, Maloy KJ, et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 2010; 464: 1371-5.
64. Wang M, Tan Z, Zhang R, Kotenko SV, Liang P. Interleukin 24 (MDA-7/MOB-5) signals through two heterodimeric receptors, IL-22R1/IL-20R2 and IL 20R1/IL-20R2. J Biol Chem 2002; 277: 7341-7.
65. Fallon PG, Ballantyne SJ, Mangan NE, Barlow JL, Dasvarma A, Hewett DR, et al. Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion. J Exp Med 2006; 203: 1105-16.
66. Hor S, Pirzer H, Dumoutier L, Bauer F, Wittmann S, Sticht H, et al. The T-cell lymphokine interleukin-26 targets epithelial cells through the interleukin-20 receptor 1 and interleukin-10 receptor 2 chains. J Biol Chem 2004; 279: 33343-51.
67. Ouaked N, Mantel PY, Bassin C, Burgler S, Siegmund K, Akdis CA, et al. Regulation of the foxp3 gene by the Th1 cytokines: The role of IL-27-induced STAT1. J Immunol 2009; 182: 1041-9.
68. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63-8.
69. Diveu C, Lak-Hal AH, Froger J, Ravon E, Grimaud L, Barbier F, et al. Predominant expression of the long isoform of GP130-like (GPL) receptor is required for interleukin-31 signaling. Eur Cytokine Netw 2004; 15: 291-302.
70. Dinarello CA, Kim SH. IL-32, a novel cytokine with a possible role in disease. Ann Rheum Dis 2006; 65(3): iii 61-4.
71. Schmitz J, Owyang A, Oldham E, SongY, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T-helper type 2-associated cytokines. Immunity 2005; 23: 479-90.
72. Droin N, Solary E. CSF1R, CSF-1, and IL-34, a "menage a trois" conservedacross vertebrates. J Leukoc Biol 2010; 87: 745-7.
73. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450: 566-9.
74. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 2010; 11: 1014-22.
75. Vilcek J, Lee TH. Tumor necrosis factor. J Biol Chem 1991; 266: 7313-6.
76. Beutler B, Cerami A. The common mediator of shock, cachexia, and tumor necrosis. Adv Immunol 1988; 42: 213-31.
77. Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nature Med 1996; 2: 449-56.
78. Metcalf D. The colony stimulating factors. Discovery, development, and clinical applications. Cancer 1990; 65: 2185-95.
79. Border WA, Ruoslahti E. Transforming growth factor-β in disease: The dark side of tissue repair. J Clin Invest 1992; 90: 1-7.
80. Maeyer E. De, Maeyer-Guignard J. De. Interferons. In: The Cytokine Handbook. Ed: Thomson A., Academic Press, San Diego, CA. 1994.
81. Okamura H, Tsutsui H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, et al. Cloning of a new cytokine that induces IFN-production by T-cells. Science 1995; 378: 88-91.
82. Okayama Y, Kawakami T. Development, migration, and survival of mast-cells. Immunol 2006; 34: 97-115.
83. Galli SJ, Grimbaldeston M, Tsai M. Immunomodulatory mastcells: Negative, as well as positive, regulators of immunity. Nat Rev Immunol 2008; 8: 478-86.
84. Metz M, Maurer M. Mast-cells-key effector cells in immune responses. Trends Immunol 2007; 28: 234-41.
85. Kneilling M, Rocken M. Mast-cells: Novel clinical perspectives from recent insights. Exp Dermatol 2009; 18: 488-96.
86. Rivera J, Gilfillan AM. Molecular regulation of mast cell activation. J Allergy Clin Immunol 2006; 117:1214-25.
87. Kalesnikoff J, Galli SJ. New developments in mast cell biology. Nat Immunol 2008; 9: 1215-23.
88. Boyce JA. Mast-cells: Beyond IgE. J Allergy Clin Immunol 2003; 111: 24-32.
89. Yu M, Tsai M, Tam SY, Jones C, Zehnder J, Galli SJ. Mast-cells can promote the development of multiple features of chronic asthma in mice. J Clin Invest 2006; 116: 1633-41.
90. Katz HR. Inhibitory receptors and allergy. Curr Opin Immunol 2002; 14: 698-704.
91. Gilfillan AM, Tkaczyk C. Integrated signalling pathways for mastcell activation. Nat Rev Immunol 2006; 6: 218-30.
92. Daeron M. Fc receptor biology. Annu Rev Immunol 1997; 15: 203-4.
93. Cherwinski HM, Murphy CA, Joyce BL, Bigler ME, Song YS, Zurawski SM, et al. The CD200 receptor is a novel and potent regulator of murine and human mast cell function. J Immunol 2005; 174: 1348-56.
94. Lu-Kuo JM, Joyal DM, Austen KF, Katz HR. gp49B1 Inhibits IgEinitiated mast cell activation through both immunoreceptor tyrosine-based inhibitory motifs, recruitment of src homology 2 domain-containing phosphatase-1, and suppression of early and late calcium mobilization. J Biol Chem 1999; 274: 5791-6.
95. Bachelet I, Munitz A, Moretta A, Moretta L, Levi-Schaffer F. The inhibitory receptor IRp60 (CD300a) is expressed and functional on human mast-cells. J Immunol 2005; 175: 7989-95.
96. Uehara T, Blery M, Kang DW, Chen CC, Ho LH, Gartland GL, et al. Inhibition of IgE-mediated mast cell activation by the paired Ig-like receptor PIR-B. J Clin Invest 2001; 108: 1041-50.
97. Min B. Basophils: What they "can do" versus what they "actually do". Nat Immunol 2008; 9: 1333-9.
98. th Ed St Louis: Mosby Elsevier; 2009.
99. th Ed St Louis: Mosby Elsevier; 2009.
100. Sullivan BM, Locksley RM. Basophils: A non redundant contributor to host immunity. Immunity 2009; 30: 12-20.
101. Sokol CL, Barton GM, Farr AG, Medzhitov R. A mechanism for the initiation of allergen-induced T-helper type 2 responses. Nat Immunol 2008; 9: 310-8.
102. Karasuyama H, Mukai K, Tsujimura Y, Obata K. Newly discovered roles for basophils: Neglected minority gains new respect. Nat Rev Immunol 2009; 9: 9-13.
103. Mukai K, Obata K, Tsujimura Y, Karasuyama H. New insights into the roles for basophils in acute and chronic allergy. Allergol Int 2009; 58(1): 11-9.
104. Mosser, DM, Edwards, JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958-69.
105. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23-35.
106. Erwig LP, Henson PM. Immunological consequences of apoptotic cell phagocytosis. Am J Pathol 2007; 171: 2-8.
107. Murray PJ, Wynn TA. Obstacles and opportunities for understanding macrophage polarization. J Leukoc Biol 2011; 89; 557-63.
108. Otterness IG, Vande Loo FAJ, Blive L. Mechanisms and models in rheumatoid arthritis. In: Henderson B, Edwards JCW, Pettipher ER, Eds Cytokines in Models of Arthritis. San Diego: Academic Press, 1995; 485-505.
109. Cutolo M, Sulli A, Barone A, Seriolo B, Accardo S. Macrophages, synovial tissue and rheumatoid arthritis. Clin Exp Rheumatol 1993; 11: 331-9.
110. Vinay DS, Kwon BS. The tumor necrosis factor/TNF receptor superfamily: Therapeutic targets in autoimmune diseases. Clin Exp Immunol. 2011; 162: 145-57.
111. Tang C, Ward C, Reid D, Bish R, O'Byrne PM, Walters EH. Normally suppressing CD40 coregulatory signals delivered by airway macrophages to TH2 lymphocytes are defective in patients with atopic asthma. J Allergy Clin Immunol 2001; 107: 863-70.
112. Hume DA. The mononuclear phagocyte system. Curr Opin Immunol 2006; 18:49-53.
113. + blood monocytes: Their role in infection and inflammation. J Leukoc Biol 2007; 81: 584-92.
114. Said EA, Trautmann L, Dupuy FP, Zhang Y, Shi Y, Hill BJ, et al. PD-1 Induced IL10 production by monocytes impairs T-cell activation in a reversible fashion. Nat Med 2010; 452-9.
115. Van Furth R, Diesselhoff-den Dulk, MM, Mattie H. Quantitative study on the production and kinetics of mononuclear phagocytes during an acute inflammatory reaction. J Exp Med 1973; 138: 1314-30.
116. + monocytes by glucocorticoid therapy. Clin Exp Immunol 1998; 112: 501-6.
117. Lambrecht BN, Hammad H. The role of dendritic and epithelial cells as master regulators of allergic airway inflammation. Lancet 2010; 376: 835-43.
118. Jakubzick C, Tacke F, Llodra J, van Rooijen N, Randolph GJ. Modulation of dendritic cell trafficking to and from the airways. J Immunol 2006; 176: 3578-84.
119. Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: Sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 2008; 8: 594-606.
120. Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006; 25: 383-92.
121. Ronnblom L, Pascual V. The innate immune system in SLE: Type I interferons and dendritic cells. Lupus 2008; 17: 394-9.
122. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 2000; 16: 111-35.
123. Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T-cells, bone loss, and mammalian evolution. Annu Rev Immunol 2002; 20: 795-823.
124. Kuipers H, Lambrecht BN. The interplay of dendritic cells, Th2 cells and regulatory T-cells in asthma. Curr Opin Immunol 2004; 16: 702-8.
125. Lambrecht BN, De Veerman M, Coyle AJ, Gutierrez-Ramos JC, Thielemans K, Pauwels RA. Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation. J Clin Invest 2000; 106: 551-9.
126. Woolley MJ, Denburg JA, Ellis R, Dahlback M, O'Byrne PM. Allergen-induced changes in bone marrow progenitors and airway responsiveness in dogs and the effect of inhaled budesonide on these parameters. Am J Resp Cell Mol Biol 1994; 11: 600-6.
127. Gleich GJ. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 2000; 105: 651-63.
128. Robinson DS, Kay AB, Wardlaw AJ. Eosinophils. Clin Allergy Immunol 2002; 16: 43-75.
129. th Ed St Louis: Mosby Elsevier; 2009.
130. Blanchard C, Rothenberg ME. Biology of the eosinophil. Adv Immunol 2009; 101: 81-121.
131. Rosenberg HF, Phipps S, Foster PS. Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol 2007; 119: 1303-12.
132. Chanez P, Dent G, Yukawa T, Barnes PJ, Chung KF. Generation of oxygen free radicals from blood eosinophils from asthma patients after stimulation with PAF or phorbol ester. Eur Respir J 1990; 3: 1002-7.
133. Evans DJ, Lindsay MA, O'Connor BJ, Barnes PJ. Priming of circulating human eosinophils following exposure to allergen challenge. Eur Respir J 1996; 9: 703-8.
134. th Ed St Louis: Mosby Elsevier; 2009.
135. Hogan SP, Rosenberg HF, Moqbel R, Phipps S, Foster PS, Lacy P, et al. Eosinophils: Biological properties and role in health and disease. Clin Exp Allergy 2008; 38: 709-50.
136. Munitz A, Levi-Schaffer F. Inhibitory receptors on eosinophils: A direct hit to a possible Achilles heel? J Allergy Clin Immunol 2007; 119: 1382-7.
137. Park CS, Choi YS, Ki SY, Moon SH, Jeong SW, Uh ST, et al. Granulocyte macrophage colony-stimulating factor is the main cytokine enhancing the survival of eosinophils in asthmatic airways. Eur Respir J 1998; 12: 872-8.
138. Simon HU. Regulation of eosinophil and neutrophil apoptosissimilarities and differences. Immunol Rev 2001; 179: 156-62.
139. Kips JC, O'Connor BJ, Langley SJ, Woodcock A, Kerstjenens HAM, Postma DS, et al. Results of a Phase I trial with SCH55700, a humanized anti-IL-5 antibody in severe persistent asthma. Am J Resp Crit Care Med 2000; 161: A505.
140. Kaufmann SHE. Immunology's foundation: The 100-year anniversary of the Nobel Prize to Paul Ehrlich and Elie Metchnikoff. Nat Immunol 2008; 9: 705-12.
141. Lindbom L. Regulation of vascular permeability by neutrophils in acute inflammation. Chem Immunol Allergy 2003; 83:146-66.
142. Engelhardt B, Vestweber D. The Multistep Cascade of Leukocyte Extravasation. In: Shepro, D. (Ed.), Microvascular Research: [biology and pathology]. Elsevier Academic Press, Amsterdam; Boston, 2006; 303-16.
143. Nathan C. Neutrophils and immunity: Challenges and opportunities. Nat Rev Immunol 2006; 6, 173-82.
144. Monteseirin J. Neutrophils and asthma. J Investig Allergol Clin Immunol 2009; 19: 340-54.
145. Fahly JV. Eosinophilic and neutrophilic inflammation in asthma. Proc Am Thorac Soc 2009; 6: 256-9.
146. Faurschou M, Borregaard N. Neutrophil granules and secretory vesicles in inflammation. Microbes Infect 2003; 5, 1317-27.
147. Gullberg U, Bengtsson N, Bülow E, Garwicz D, Lindmark A, Olsson I. Processing and targeting of granule proteins in human neutrophils. J Immunol Methods 1999; 232: 201-10.
148. Hansson M, Olsson I, Nausseef WM. Biosynthesis, processing and sorting of human myeloperoxidase. Arch Biochem Biophys 2006; 445: 214-24.
149. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 2011; 11: 519-31.
150. Lee WL, Downey GP. Neutrophil activation and acute lung injury. Curr Opin Crit Care 2001; 7: 1-7.
151. Huntington ND, Vosshenrich CA, Di Santo JP. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol 2007; 7: 703-14.
152. Biassoni R, Cantoni C, Marras D, Giron-Michel J, Falco M, Moretta L, et al. Human natural killer cell receptors: Insights into their molecular function and structure. J Cell Mol Med 2003; 7: 376-87.
153. Flodstrom-Tullberg M, Bryceson YT, Shi FD, Hoglund P, Ljunggren HG. Natural killer cells in human autoimmunity. Curr Opin Immunol 2009; 21: 634-40.
154. + natural killer T-cells in bronchial asthma. N Engl J Med 2006; 354: 1117-29.
155. Kim HY, DeKruyff RH, Umetsu DT. The many paths to asthma: Phenotype shaped by innate and adaptive immunity. Nat Immunol 2010; 11: 577-84.
156. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008; 118: 3546-56.
157. Tran CN, Lundy SK, Fox DA. Synovial biology and T-cells in rheumatoid arthritis. Pathophysiology 2005; 12: 183-9.
158. Foey A, Green P, Foxwell B, Feldmann M, Brennan F. Cytokinestimulated T-cells induce macrophage IL-10 production dependent on phosphatidylinositol 3-kinase and p70S6K: Implications for rheumatoid arthritis. Arthritis Res 2002; 4 (1): 64-70.
159. Larche M, Robinson DS, Kay AB. The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol 2003; 111: 450-63.
160. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: An overview. Methods Enzymol 1990; 186: 1-85.
161. Rahman I, MacNee W. Lung glutathione and oxidative stress: Implications in cigarette smoke-induced airways disease. Am J Physiol 1999; 277: L1067-88.
162. Rahman I, MacNee W. Oxidative stress and regulation of glutathione synthesis in lung inflammation. Eur Respir J 2000b; 16: 534-54.
163. Rahman I, MacNee W. Role of transcription factors in inflammatory lung diseases. Thorax 1998; 53: 601-12.
164. Rahman I, MacNee W. Regulation of redox glutathione levels and gene transcription in lung inflammation: Therapeutic approaches. Free Radic Biol Med 2000a; 28, 1405-20.
165. Haddad JJ. Antioxidant and prooxidant mechanisms in the regulation of redox(y)-sensitive transcription factors. Cell Signal 2002; 14: 879-97.
166. Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: Role in inflammatory disease and progression to cancer. Biochem J 1996; 313: 17-29.
167. Bruckdorfer KR. Lipid oxidation products and vascular function. Free Radic Res 1998; 28: 573-81.
168. Tiku ML, Gupta S, Deshmukh DR. Aggrecan degradation in chondrocytes is mediated by reactive oxygen species and protected by antioxidants. Free Radic Res 1999; 30: 395-405.
169. Davies KJ. Protein damage and degradation by oxygen radicals. I. General aspects. J Biol Chem 1987; 262: 9895-901.
170. Martel-Pelletier J, Alaaeddine N, Pelletier JP. Cytokines and their role in the pathophysiology of osteoarthritis. Front Biosci 1999; 4: 694-703.
171. Yudoh K, Nguyen T, Nakamura H, Hongo-Masuko K, Kato T, Nishioka K. Potential involvement of oxidative stress in cartilage senescence and development of osteoarthritis: Oxidative stress induces chondrocyte telomere instability and downregulation of chondrocyte function. Arthritis Res Ther 2005; 7: 380-91.
172. Loeser RF, Carlson CS, Del Carlo M, Cole A. Detection of nitrotyrosine in aging and osteoarthritic cartilage: Correlation of oxidative damage with the presence of interleukin-1beta and with chondrocyte resistance to insulin-like growth factor 1. Arthritis Rheum 2002; 46: 2349-57.
173. Henrotin YE, Bruckner P, Pujol JP. The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthritis Cartilage 2003; 11: 747-55.
174. AfonsoV, Santos G, Collin P, Khatib AM, Mitrovic D, Lomri N, et al. TNFβ down-regulates human Cu/Zn superoxide dismutase 1 promoter via JNK/AP-1 signaling pathway. Free Radic Biol Med 2006; 41: 709-21.
175. Stralin P, Marklund SL. Multiple cytokines regulate the expression of extracellular superoxide dismutase in human vascular smooth muscle cells. Atherosclerosis 2000; 151: 433-41.
176. Adachi T, Toishi T, Takashima E, Hara H. Infliximab neutralizes the suppressive effect of TNF-alpha on expression of extracellularsuperoxide dismutase in vitro. Biol Pharm Bull 2006; 29: 2095-8.
177. Marklund SL. Human copper-containing superoxide dismutase of high molecular weight. Proc Natl Acad Sci USA 1982; 79: 7634-8.
178. Terkeltaub R, Zachariae C, Santoro D, Martin J, Peveri P, Matsushima K. Monocyte-derived neutrophil chemotactic factor/interleukin-8 is a potential mediator of crystal-induced inflammation. Arthritis Rheum 1991; 34: 894-903.
179. Morrow JD, Roberts LJ. The isoprostanes: Unique bioactive products of lipid peroxidation. Prog Lipid Res 1997; 36: 1-21.
180. Parola M, Bellomo G, Robino G, Barrera G, Dianzani MU. 4-Hydroxynonenal as a biological signal: Molecular basis and pathophysiological implications. Antioxid Redox Signal 1999; 1: 255-84.
181. Uchida K, Shiraishi M, Naito Y, Torii N, Nakamura Y, Osawa T. Activation of stress signaling pathways by the end product of lipid peroxidation. J Biol Chem 1999; 274: 2234-42.
182. Johnson F, Giulivi C. Superoxide dismutases and their impact upon human health. Mol Aspects Med 2005; 26: 340-52.
183. Morten KJ, Ackrell BA, Melov S. Mitochondrial reactive oxygen species in mice lacking superoxide dismutase 2: Attenuation via antioxidant treatment. J Biol Chem 2006; 281: 3354-9.
184. Fattman CL, Schaefer LM, Oury TD. Extracellular superoxide dismutase in biology and medicine. Free Radic Biol Med 2003; 35: 236-56.
185. Enghild JJ, Thogersen IB, Oury TD, Valnickova Z, Hojrup P, Crapo JD. The heparin-binding domain of extracellular superoxide dismutase is proteolytically processed intracellularly during biosynthesis. J Biol Chem 1999; 274: 14818-22.
186. Mates M. Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology. Toxicology 2000; 153: 83-104.
187. Biswas SK, Rahman I. Environmental toxicity, redox signaling and lung inflammation: The role of glutathione. Mol Aspects Med 2009; 30(1-2): 60-76.
188. Rahman I, MacNee W. Oxidative stress and regulation of glutathione in lung inflammation. Eur Respir J 2000b; 16: 534-54.
189. Lowry MH, McAllister BP, Jean JC, Brown LA, Hughey RP, Cruikshank WW, et al. Lung lining fluid glutathione attenuates IL-13 induced asthma. Am J Respir Cell Mol Biol 2008; 38: 509-16.
190. Lailey AF, Hill L, Lawston IW, Stanton D, Upshall DG. Protection by cysteine esters against chemically induced pulmonary oedema. Biochem Pharmacol 1991; 42: S47-S54.
191. Park EM, Park YM, Gwak YS. Oxidative damage in tissues of rats exposed to cigarette smoke. Free Radic Biol Med 1998; 25(1): 79-86.
192. Cuzzocrea S, Costantino G, Zingarelli B, Mazzon E, Micali A, Caputi AP. The protective role of endogenous glutathione in carrageenan-induced pleurisy in the rat. Eur J Pharmacol 1999; 372(2): 187-97.
193. Haddad JJ. L-Buthionine-(S, R)-sulfoximine, an irreversible inhibitor of gamma-glutamylcysteine synthetase, augments LPS-mediated proinflammatory cytokine biosynthesis: Evidence for the implication of an IkappaB-alpha/NF-kappaB insensitive pathway. Eur Cytokine Netw 2001; 12(4): 614-24.
194. Hayes JD, McLellen LI. Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Rad Res 1999; 31: 273-300.
195. Pastoret A, Federici G, Bertini E, Piemonti F. Analysis of glutathione: Implication in redox and detoxification. Clin Chim Acta 2003; 333: 19-39.
196. Comhair SA, Erzurum SC. The regulation and role of extracellular glutathione peroxidase. Antioxid Redox Signal 2005; 7(1-2): 72-9.
197. Rahman I, Biswas SK, Jimenez LA, Torres M, Forman J. Glutathione, stress responses, and redox signaling in lung inflammation. Antioxid Redox Signal 2005; 7: 42-59.
198. Saleh D, Ernest P, Lim S, Barnes PJ, Giaid A. Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is with induction of nitric oxide synthase: Effect of inhaled glucocorticoid. FASEB J 1998; 12: 929-37.
199. Kanazawa H, Kurihara N, Hirata K, Takeda T. The role of free radicals in airway obstruction in asthmatic patients. Chest 1991; 100:1319-22.
200. Meister A. Glutathione metabolism and its selective modification. J Biol Chem 1988; 263(33): 17205-8.
201. Carlo MD, Loeser RF. Increased oxidative stress with aging reduces chondrocyte survival: Correlation with intracellular glutathione levels. Arthritis Rheum 2003; 48: 3419-30.
202. Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, et al. Enhanced cleavage of type ll collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997; 99: 1534-45.
203. Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: A microsomal, glutathionedependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci USA 1999; 96: 7220-5.
204. Li G, Chen Y, Saari JT, Kang YJ. Catalase-overexpressing transgenic mouse heart is resistant to ischemia-reperfusion injury. Am J Physiol 1997; 273: H1090-5.
205. Reynaert NL, Aesif SW, McGovern T, Brown A, Wouters EF, Irvin CG, et al. Catalase overexpression fails to attenuate allergic airways disease in the mouse. J Immunol 2007; 178(6): 3814-21.
206. Odajima N, Betsuyaku T, Nagai K, Moriyama C, Wang DH, Takigawa T, et al. The role of catalase in pulmonary fibrosis. Respir Res 2010; 11: 183.
207. Schalkwijk J, van den Berg WB, van de Putte LBA, Joosten LAB, van den Bersselaar L. Cationization of catalase, peroxidase, and superoxide dismutase effect of improved intraarticular retention on experimental arthritis in mice. J Clin Invest 1985; 76(1): 198-205.
208. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
209. Mashimo H, Goyal RK. Lessons from genetically engineered animal models. IV. Nitric oxide synthase gene knockout mice. Am J Physiol 1999; 277: G745-50.
210. Slomiany BL, Slomiany A. Activation of peroxisome proliferatoractivated receptor gamma impedes Porphyromonas gingivalis lipopolysaccharide interference with salivary mucin synthesis through phosphatidylinositol 3-kinase/erk pathway. J Physiol Pharmacol 2003; 54: 3-15.
211. Coleman JW. Nitric oxide in immunity and inflammation. Int Immunopharmacol 2001; 1:1397-406.
212. Pountos I, Georgouli T, Bird H, Giannoudis PV. Nonsteroidal antiinflammatory drugs: Prostaglandins, indications, and side effects. Int J Infereron Cytokine Mediator Res 2011; 3(1): 19-27.
213. Hawkey CJ. Non steroidal anti-inflammatory drug gastropathy. Gastroenterology 2000; 119: 521-35.
214. Laine L. GI risk and risk factors of NSAIDs. J Cardiovasc Pharmacol 2006; 47(1):S60-6.
215. Romanovsky AA, Almeida MC, Aronoff DM, Ivanov AI, Konsman JP, Steiner AA, et al. Fever and hypothermia in systemic inflammation: Recent discoveries and revisions. Front Biosci 2005; 10: 2193-216.
216. Osen NJ, Stein MC. Drug therapy: New drugs for rheumatoid arthritis. N Engl J Med 2004; 350(21): 2167-79.
217. Burian M, Geisslinger G. COX-dependent mechanisms involved in the anti-nociceptive action of NSAIDs at central and peripheral sites. Pharmacol Ther 2005; 107: 139-54.
218. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other nonsteroidal anti-inflammatory drugs. J Biol Chem 1993; 268:6610-4.
219. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Natl Acad Sci USA 1999; 96: 7563-8.
220. Seibert KY, Zhang K, Leahy S, Hauser J, Masferrer W, Perkins L et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994; 91:12013-7.
221. Chenevard R, Hurlimann D, Bechir M, Enseleit F, Spieker L, Hermann M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circ J Am Heart Assoc 2003; 107:405-9.
222. rd edition, Oxford University Press Inc., New York 2004: 442-50.
223. th ed. 1994; 767-80.
224. Assanasen P, Naclerio RM. Anti-allergic, anti-inflammatory effects of H1-antihistamines in humans. Clin Allergy Immunol 2002; 17: 101-39.
225. Sohei M, Makoto F, Naoto F. Efficacy and safety of methylxanthines in the treatment of asthma. Allergol Int 2004; 53(1): 13-22.
226. Cazzola M, Calzetta L, Matera MG. Beta (2)-adrenoceptor agonists: Current and future direction. Br J Pharmacol 2011; 163: 4-17.
227. Ray NC, Alcaraz L. Muscarinic antagonist-beta-adrenergic agonist dual pharmacology molecules as bronchodilators: A patent review. Expert Opin Ther Pat 2009; 19: 1-12.
228. Yang Y, Lu JY, Wu X, Summer S, Whoriskey J, Saris C, et al. Gprotein-coupled receptor 35 is a target of the asthma drugs cromolyn disodium and Nedocromil sodium. Pharmacology 2010; 86: 1-5.
229. O'Byrne PM, Israel E, Drazen JM. Antileukotrienes in the treatment of asthma. Ann Intern Med 1997; 127: 472-80.
230. Rubin P, Dubé L, Braeckman R, Swanson L, Hansen R, Albert D, et al. Pharmacokinetics, safety and ability to diminish leukotriene synthesis by zileuton, an inhibitor of the 5-lipoxygenase. Agents Actions Suppl 1991; 35: 103-16.
231. Houslay MD, Schafer P, Zhang KY. Keynote review: Phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005; 10: 1503-19.
232. Barnes PJ. Glucocorticosteroids: Current and future directions. Br J Pharmacol 2011; 163: 29-43.
233. Aggarwal BB, Shishodia S, Surh Y-J. The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease. New York: Springer Publishers; 2006.
234. Singh BB, Mishra LC, Vinjamury SP, Aquilina N, Singh VJ, Shepard N. The effectiveness of Commiphora mukul for osteoarthritis of the knee: An outcomes study. Altern Ther Health Med 2003; 9: 74-9.
235. Ahmad SF, Khan B, Bani S, Suri KA, Satti NK, Qazi GN. Amelioration of adjuvant-induced arthritis by ursolic acid through altered Th1/Th2 cytokine production. Pharmacol Res 2006; 53: 233-40.
236. Ichikawa H, Takada Y, Shishodia S, Jayaprakasam B, Nair MG, Aggarwal BB. Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-kappaB (NF-kappaB) activation and NF-kappaB-regulated gene expression. Mol Cancer Ther 2006; 5: 1434-45.
237. Mamani-Matsuda M, Kauss T, Al-Kharrat A, Rambert J, Fawaz F, Thiolat D, et al. Therapeutic and preventive properties of quercetin in experimental arthritis correlate with decreased macrophage inflammatory mediators. Biochem Pharmacol 2006; 72: 1304-10.
238. Ivanovska N, Philipov S, Hristova M. Influence of berberine on Tcell mediated immunity. Immunopharmacol Immunotoxicol 1999; 21: 771-86.
239. Ammon HP. Salai guggal-Boswellia serrata: From a herbal medicine to a specific inhibitor of leukotriene biosynthesis. Phytomedicine 1996; 3: 67-70.
240. Hu L, Chen Z, Xie Y, Jiang Y, Zhen H. Alkyl and alkoxycarbonyl derivatives of ginkgolide B: Synthesis and biological evaluation of PAF inhibitory activity. Bioorg Med Chem 2000; 822: 1515-21.
241. Abourashed E, El-Alfy A, Khan I, Walker L. Ephedra in perspective--a current review. Phytother Res 2003; 17(7): 703-12.
242. Sampath Kumar KP, Bhowmik D, Chiranjit, Tiwari P, Kharel R. Indian traditional herbs Adhatoda vasica and its medicinal application. J Chem Pharm Res 2010; 2(1): 240-5.
243. Shin Y, Bae E, Lee B, Lee SH, Kim JA, Kim Y, et al. In vitro and in vivo anti-allergic effects of Glycyrrhiza glabra and its components. Planta Medica 2007; 73: 257.
244. Wen MC, Wei CH, Hu ZQ, Srivastava K, Ko J, Xi ST, et al. Efficacy and tolerability of anti-asthma herbal medicine intervention in adult patients with moderate-severe allergic asthma. J Allergy Clin Immunol 2005; 116: 517-24.
245. Wang, T., Lai, C.S. Hydroxamate derivatives of non-steroidal antiinflammatory drugs. US6620813 (2003).
246. Jain, R., Jinda, K.C., Singh, S. Compositions comprising glycosaminoglycan and non steroidal anti inflammatory. US0261866 (2008).
247. Salvemini, D. Combinations of superoxide dismutase mimetics and non steroidal analgesic/anti inflammatory drugs. US0270639 (2006).
248. Cheng, H., Hu, X., Jerome, K.D., Obukowicz, M., Olson, L., Rucker, P.V., Webber, R.K. Tricyclic compounds, compositions and methods. US20120088802 (2012).
249. Tran, D.V., Tran, D.N. Product typically based on salt of peroxy mono sulphuric acid and suitable for medicinal usage and associated product fabrication. US0074014 (2012).
250. Shoutov, D. Red grape dry composition and health tea. US0247670 (2010).
251. Ellerby, L.M., Ellman, Jonathan, A. Caspase inhibitors and uses thereof. US0230527 (2011).
252. Muralidhar, T.G., Potin, D., Maillet, M.B., Launay, M., Malmaison, R., Iwanowicz, E.Z. Hexahydro benzimidazolone compounds useful as anti-inflammatory agents. US6974815 (2005).
253. Pelletier, P.J., Pelletier, M. Use of annellated pyrrole compounds in the treatment of articular cartilage. US7425573 (2008).
254. Crawford, T.C., Eliasof, S., Gangal, G., Ng, P., Reiter, L. A. Polymer-agent conjugates, particles, compositions, and related methods of use. US0268658 (2011).
255. Ghayur, T., Liu, J., Manoj, S., Brophy, S.E. Dual variable domain immunoglobulins and uses thereof. US0091372 (2011).
256. Miyamoto, K., Yasuda, Y., Yoshioka, K. Hyaluronic acid derivative and drug containing the same. US0083991 (2011).
257. Matteo, D., Giovanni, G. New medicines for topic use based on sulfated hyaluronic acid as activating or inhibiting agent of the cytokine activity. US20120121572 (2012).
258. Gonsalves, A.R., Manuel, A., Jose, D.B., Serra, C.A., Vieira, F.S., Catarina, A., Rui, D.A., Gonsalves, D.C., Maria, A., Figueras, R., Rita, A. Process to produce a Diclofenac cyclodextrin conjugate. EP2422818 (2012).
259. Mary, P., Remy, P., Jean-Jacques, F., Damien, P., Severine, F., Jean-Luc, D., Cedric-Olivier, T., Anne-Marie, C., Jean-Pierre, M., Olivier, R. Phosphorylated dendrimers as anti-inflammatory drugs. EP2341915 (2011).
260. Arita, M., Aria, H., Isobe, Y., Kubota, T. Novel anti-inflammatory metabolite derived from omega-3-type fatty acid. WO2012023254 (2012).
261. Qi, J., Yuan, Z. Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent. EP2444093 (2012).
262. Rodgers, J.D., Zhu, W., Glenn, J. Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors. WO2012068440 (2012).
263. Biggadike, K., Diallo, H., House, D., Macdonald, S.J., F., Mclay, I.M. N-(2 {[1-Phenyl-1H-indazol-4-yl] amino} propyl)-sulfonamide derivatives as non-steroidal glucocorticoid receptor ligands for the treatment of inflammations. WO2012068440 (2012).
264. Chu, L., Ogawa, A., Ok, H.O., Ujjainwalla, F. Benzimidazole and aza-benzimidazole carboxamides. US0207750 (2011).
265. Eiffe, E., Heaton, A., Walker, C., Husband, J.A. 2-Substituted isoflavonoid compounds, medicaments and uses. US0166142 (2011).
266. Prosper, P., Antonio, J., Martín, C., Naranjo, N.E., Pedro, M.P., Concepción, Redo, A., Jesús, V., Fontelles, M., Moreno, M. I., Rocio, Robles, S., Ma, E. 3-Indazolyl ether family with cannabinoid and/or cholinergic properties. WO2011039388 (2011).
267. Paez, P.J.A., Gonzales, N.P., Perez, M.C., Aran, R.V. J., Martin, F.M.I., Giron, M.R., Sanchez, R., Eva, M. Treatment drug for autoimmune diseases and allergic diseases. WO2011039388 (2011).
268. Demin, V.A., Martianov, A.V., Shuster, M.A. Protein kinase c inhibitors exhibiting an anti-inflammatory, anti-allergic and antiasthma effect. WO2010064958 (2010).
269. Moon, J.J., Sook, L.S., Bum, K.K., Gene, L.E. Composition comprising an extract of a mixture of crude drugs consisting of Artemisia princeps var. orientalis, guava leaves, morus-alba linne, and gr-ape seeds with anti-allergic rhinitis, anti-atopic dermatitis and anti-asthma activities. KR1020080027539 (2008).
270. Bohnert, G., Chen, S. Tetrazolyl-tetrahydropyridine compounds for inflammation and immune-related uses WO2012064808 (2012).
271. King-Underwood, J., Ito, K., Murray, J.P., Hardy, G., Brookfield, A.F., Brown, J.C. Quinazolin-4 (3H)-one derivatives used as pI3 kinase inhibitors. WO2012052753 (2012).
272. Lipson, K.E. Anti-connective tissue growth factor agent for use in the treatment of lung remodelling disease. WO2012061811 (2012).
273. Alder, M.C., Baldwin, R.I., Barton, P.N., Campbell, J.A., Champigny, C.A., Harling, D.J., Maxwell, C.A., Simpson, K.J., Smith, David, I. E., Tame, J.C., Wilson, C., Woolven, M.J. Derivatives of 2-[2-(benzo-or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratory, allergic or inflammatory diseases. WO2011110575 (2011).
274. Boehm, J.C., Davis, R.S., Kerns, J.K., Lin, G., Nie, H. Voltagegated sodium channel blockers. WO2011088201 (2011).
275. Ashman, C., Ellis, J.H., Hamblin, A.P., Lewis, P.A., Orecchia, M.A. IL-13 binding protein (anti IL-13 MAb's). WO2010136481 (2010).
276. Baker, D., Bruce, M., Cahn, A., Thomas, M. Novel combination of therapeutic agents (muscarinic antagonist and 2 agonist). WO2010097114 (2010).
277. Day, C.J., Douillet, J., Bruno, F., Darko, K., Leanda, J., Kragol, G., Marusic-Istuk, Z. Anti-inflammatory macrolide (3'-N-demethyl-4'-O-(2-diethylaminoethanoyl)-6-O-methyl-9β-aza-9β-homoerythromycin A). WO2010086349 (2010).
278. Bone, G. Pharmaceutical composition comprising a non-steroidal glucocorticoid receptor agonist in combination with a dual histamine antagonist. WO2009153296 (2009).
279. Bone, G. Pharmaceutical compositions comprising n-[2-(2R)-2-{[4-[(4-chlorophenyl) methyl]-l-oxo-2(IH)-phthalazinyl] methyl}-lpyrrolidinyl) ethyl]-4-(methyloxy) butanamide. WO2009150101 (2009).
280. Bone, G., Brown, O.R., Gore, M.P., Hancock, P.A., Hodgson, T.S., Kindon, J.L., Noble, P.M. Combination of fluticasone furoate with 4-[(4-chlorophenyl) methyl]-2-({ (2R)-I-[4-(4-{ [3-(hexahydrolH-azepin-l-yl) propyl] oxy} phenyl) butyl]-2-pyrrolidinyl} methyl)-1 (2H)-phthalazinone. WO2009050159 (2009).
281. Biggadike, K., Cooper, A., William, J., House, D., Mclay, I.M., Robinson, J., Weingarten, E., Gordon, G. Indazoles as glucocorticoid receptor ligands. WO2009050244 (2009).
282. Gore, M.P., Hancock, P.A., Hodgson, T.S., Kranz, J.M., Procopiou, A.P., Vile, S. Quinoline derivatives used to treat inflammatory and allergic diseases WO2009050204 (2009).
283. Gore, P., Martin, L., Brian, E., Procopiou, P., Alexandrou, V.S. Phthalazine and pyrido [3, 4-D] pyridazine compounds as H1 receptor antagonists. US20100216799 (2010).
284. Delhomel, J.F., Hanf, R., Caumont-Bertrand, K. Substituted 1, 3-Diphenylpropane derivatives, preparations and uses thereof. US0136888 (2011).
285. Ogawa, A., Ok, H.O., Ondeyka, D., Ujjainwalla, F., Bunte, E.V. Biaryl carboxamides. US0230498 (2011).
286. Armitage, R.J., Escobar, J.C., Morris, A.E., Pluenneke, J.D. Use of interleukin-4 antagonists and compositions thereof. US0002913 (2011).
287. Chaudry, I., Banerjee, P. Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease. US0247613 (2011).